Impacts of CYP2C19 Polymorphism and Clopidogrel Dosing on in-Stent Restenosis: A Retrospective Cohort Study in Chinese Patients

References

• KimYH, ParkDW, AhnJM, et al. Everolimus-eluting stent implantation for unprotected left main coronary artery stenosis. The PRECOMBAT-2 (premier of randomized comparison of bypass surgery versus angioplasty using sirolimus-eluting stent in patients with left main coronary artery disease) study. JACC Cardiovasc Interv. 2012;5(7):708–717. doi:10.1016/j.jcin.2012.05.00222814775
   PubMed Web of Science ®Google Scholar
• SatoT, OnoT, MorimotoY, et al. Differences in clinical and angiographic outcomes with different drug-eluting stents in Japanese patients with and without diabetes mellitus. J Cardiol. 2012;60(5):361–366. doi:10.1016/j.jjcc.2012.07.00222890073
   PubMed Web of Science ®Google Scholar
• KandzariDE, LeonMB, MeredithI, FajadetJ, WijnsW, MauriL. Final 5-year outcomes from the Endeavor zotarolimus-eluting stent clinical trial program: comparison of safety and efficacy with first-generation drug-eluting and bare-metal stents. JACC Cardiovasc Interv. 2013;6(5):504–512. doi:10.1016/j.jcin.2012.12.12523602459
   PubMed Web of Science ®Google Scholar
• ByrneRA, JonerM, KastratiA. Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas Gruntzig lecture ESC 2014. Eur Heart J. 2015;36(47):3320–3331. doi:10.1093/eurheartj/ehv51126417060
   PubMed Web of Science ®Google Scholar
• OgitaM, MiyauchiK, KurataT, et al. Clinical impact of angiographic restenosis after bare-metal stent implantation on long-term outcomes in patients with coronary artery disease. Circ J. 2011;75(11):2566–2572. doi:10.1253/circj.CJ-11-046921828930
   PubMed Web of Science ®Google Scholar
• CornelissenA, SimsekyilmazS, LiehnE, et al. Apolipoprotein E deficient rats generated via zinc-finger nucleases exhibit pronounced in-stent restenosis. Sci Rep. 2019;9(1):18153. doi:10.1038/s41598-019-54541-z31796798
   PubMed Web of Science ®Google Scholar
• JohnsonJA, CavallariLH. Pharmacogenetics and cardiovascular disease–implications for personalized medicine. Pharmacol Rev. 2013;65(3):987–1009. doi:10.1124/pr.112.00725223686351
   PubMed Web of Science ®Google Scholar
• DestaZ, ZhaoX, ShinJG, FlockhartDA. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet. 2002;41(12):913–958. doi:10.2165/00003088-200241120-0000212222994
   PubMed Web of Science ®Google Scholar
• RuedlingerJ, PradoY, ZambranoT, et al. CYP2C19()2 polymorphism in chilean patients with in-stent restenosis development and controls. Biomed Res Int. 2017;2017:5783719. doi:10.1155/2017/578371928785581
   PubMed Web of Science ®Google Scholar
• TrenkD, HochholzerW, FrommMF, et al. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol. 2008;51(20):1925–1934. doi:10.1016/j.jacc.2007.12.05618482659
   PubMed Web of Science ®Google Scholar
• SimonT, VerstuyftC, Mary-KrauseM, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360(4):363–375. doi:10.1056/NEJMoa080822719106083
   PubMed Web of Science ®Google Scholar
• ZhangZ, ChenM, ZhangL, ZhaoQ. The impact of cytochrome 450 and Paraoxonase polymorphisms on clopidogrel resistance and major adverse cardiac events in coronary heart disease patients after percutaneous coronary intervention. BMC Pharmacol Toxicol. 2020;21(1):1. doi:10.1186/s40360-019-0378-731900240
   PubMed Web of Science ®Google Scholar
• HerbertJM, TissinierA, DefreynG, MaffrandJP. Inhibitory effect of clopidogrel on platelet adhesion and intimal proliferation after arterial injury in rabbits. Arterioscler Thromb. 1993;13(8):1171–1179. doi:10.1161/01.ATV.13.8.11718343491
   PubMed Web of Science ®Google Scholar
• HermannA, WeberAA, SchrorK. Clopidogrel inhibits platelet adhesion and platelet-dependent mitogenesis in vascular smooth muscle cells. Thromb Res. 2002;105(2):173–175. doi:10.1016/S0049-3848(01)00403-011958809
   PubMed Web of Science ®Google Scholar
• EvansDJ, JackmanLE, ChamberlainJ, et al. Platelet P2Y(12) receptor influences the vessel wall response to arterial injury and thrombosis. Circulation. 2009;119(1):116–122. doi:10.1161/CIRCULATIONAHA.107.76269019103996
   PubMed Web of Science ®Google Scholar
• ShuldinerAR, O’ConnellJR, BlidenKP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009;302(8):849–857. doi:10.1001/jama.2009.123219706858
   PubMed Web of Science ®Google Scholar
• JeongYH, KimIS, ParkY, et al. Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (accelerated platelet inhibition by a double dose of clopidogrel according to gene polymorphism) study. JACC Cardiovasc Interv. 2010;3(7):731–741. doi:10.1016/j.jcin.2010.05.00720650435
   PubMed Web of Science ®Google Scholar
• MazighiM, SaintMJ, BressonD, SzatmaryZ, HoudartE. Platelet aggregation in intracranial stents may mimic in-stent restenosis. AJNR Am J Neuroradiol. 2010;31(3):496–497. doi:10.3174/ajnr.A177819833804
   PubMed Web of Science ®Google Scholar
• FuZ, DongW, ShenM, et al. Relationship between hyporesponsiveness to clopidogrel measured by thrombelastography and in stent restenosis in patients undergoing percutaneous coronary intervention. Clin Biochem. 2014;47(16–17):197–202. doi:10.1016/j.clinbiochem.2014.08.00925160657
   PubMed Web of Science ®Google Scholar
• GuoB, TanQ, GuoD, ShiZ, ZhangC, GuoW. Patients carrying CYP2C19 loss of function alleles have a reduced response to clopidogrel therapy and a greater risk of in-stent restenosis after endovascular treatment of lower extremity peripheral arterial disease. J Vasc Surg. 2014;60(4):993–1001. doi:10.1016/j.jvs.2014.03.29324877854
   PubMed Web of Science ®Google Scholar
• Diaz-VillamarinX, Davila-FajardoCL, Martinez-GonzalezLJ, et al. Genetic polymorphisms influence on the response to clopidogrel in peripheral artery disease patients following percutaneous transluminal angioplasty. Pharmacogenomics. 2016;17(12):1327–1338. doi:10.2217/pgs-2016-005627464309
   PubMed Web of Science ®Google Scholar
• MegaJL, HochholzerW, FrelingerAR, et al. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA. 2011;306(20):2221–2228. doi:10.1001/jama.2011.170322088980
   PubMed Web of Science ®Google Scholar
• ColletJP, HulotJS, AnzahaG, et al. High doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-2 (clopidogrel and response variability investigation study 2). JACC Cardiovasc Interv. 2011;4(4):392–402. doi:10.1016/j.jcin.2011.03.00221511218
   PubMed Web of Science ®Google Scholar
• MaW, LiangY, ZhuJ, et al. Relationship of paraoxonase-1 Q192R genotypes and in-stent restenosis and re-stenting in Chinese patients after coronary stenting. Atherosclerosis. 2016;251:305–310. doi:10.1016/j.atherosclerosis.2016.07.90127450784
   PubMed Web of Science ®Google Scholar
• SchulzS, SibbingD, BraunS, et al. Platelet response to clopidogrel and restenosis in patients treated predominantly with drug-eluting stents. Am Heart J. 2010;160(2):355–361. doi:10.1016/j.ahj.2010.05.00320691843
   PubMed Web of Science ®Google Scholar
• ColletJP, HulotJS, CuissetT, et al. Genetic and platelet function testing of antiplatelet therapy for percutaneous coronary intervention: the ARCTIC-GENE study. Eur J Clin Pharmacol. 2015;71(11):1315–1324. doi:10.1007/s00228-015-1917-926265231
   PubMed Web of Science ®Google Scholar
• PriceMJ, BergerPB, TeirsteinPS, et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA. 2011;305(11):1097–1105. doi:10.1001/jama.2011.29021406646
   PubMed Web of Science ®Google Scholar
• Section of Interventional Cardiology CS, Cardiology of Chinese Medical Association, Editorial Board of Chinese Journal of Cardiology. [Chinese guideline for percutaneous coronary intervention (pocket guideline)]. Zhonghua Xin Xue Guan Bing Za Zhi. 2012;40(4):271–277.22801302
   PubMedGoogle Scholar
• DehmerGJ, BlankenshipJC, CilingirogluM, et al. SCAI/ACC/AHA expert consensus document: 2014 update on percutaneous coronary intervention without on-site surgical backup. J Am Coll Cardiol. 2014;63(23):2624–2641. doi:10.1016/j.jacc.2014.03.00224651052
   PubMed Web of Science ®Google Scholar
• Section of Interventional Cardiology of Chinese Society of Cardiology of Chinese Medical Association, Specialty Committee on Prevention and Treatment of Thrombosis of Chinese College of Cardiovascular Physicians, Editorial Board of Chinese Journal of Cardiology. [Chinese guideline for percutaneous coronary intervention (2016)]. Zhonghua Xin Xue Guan Bing Za Zhi. 2016;44(5):382–400. doi:10.3760/cma.j.issn.0253-3758.2016.05.00627220573
   PubMedGoogle Scholar
• DodgenTM, HochfeldWE, FicklH, et al. Introduction of the AmpliChip CYP450 test to a South African cohort: a platform comparative prospective cohort study. BMC Med Genet. 2013;14:20. doi:10.1186/1471-2350-14-2023356658
   PubMed Web of Science ®Google Scholar
• LvL, YeW, SongP, et al. Relationship between ALDH2 genotype and in-stent restenosis in Chinese Han patients after percutaneous coronary intervention. BMC Cardiovasc Disord. 2019;19(1):176. doi:10.1186/s12872-019-1161-931345174
   PubMed Web of Science ®Google Scholar
• Clopidogrel. 2012
   Google Scholar
• XieX, MaYT, YangYN, et al. Personalized antiplatelet therapy according to CYP2C19 genotype after percutaneous coronary intervention: a randomized control trial. Int J Cardiol. 2013;168(4):3736–3740. doi:10.1016/j.ijcard.2013.06.01423850318
   PubMed Web of Science ®Google Scholar
• ScottSA, SangkuhlK, SteinCM, et al. Clinical pharmacogenetics implementation consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. 2013;94(3):317–323. doi:10.1038/clpt.2013.10523698643
   PubMed Web of Science ®Google Scholar
• KonishiH, KatohY, TakayaN, et al. Platelets activated by collagen through immunoreceptor tyrosine-based activation motif play pivotal role in initiation and generation of neointimal hyperplasia after vascular injury. Circulation. 2002;105(8):912–916. doi:10.1161/hc0802.10525611864917
   PubMed Web of Science ®Google Scholar
• FriedmanRJ, StemermanMB, WenzB, et al. The effect of thrombocytopenia on experimental arteriosclerotic lesion formation in rabbits. Smooth muscle cell proliferation and re-endothelialization. J Clin Invest. 1977;60(5):1191–1201. doi:10.1172/JCI108872409735
   PubMed Web of Science ®Google Scholar
• UnterbergC, SandrockD, NebendahlK, BuchwaldAB. Reduced acute thrombus formation results in decreased neointimal proliferation after coronary angioplasty. J Am Coll Cardiol. 1995;26(7):1747–1754. doi:10.1016/0735-1097(95)00373-87594113
   PubMed Web of Science ®Google Scholar